Advertisement

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement

Mar

22

Today In Oncology

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

Hypofractionated Locoregional RT in Early Breast Cancer

Melanoma-Specific Survival With Sentinel Lymph Node Biopsy

Breast Cancer Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy

AMA Survey Finds Rapid Growth in Physician AI Adoption

Advertisement

© 2026 HSP News Service, L.L.C.